Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis.
Animal and laboratory studies suggest that regular use of nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce prostate cancer risk. To assess this association, we conducted a systematic review and meta-analysis of observational studies published before January 2003. We derived summary odds ratios (ORs) using both fixed and random effects models and performed subgroup analyses to explore the possible sources of heterogeneity between combined studies. We identified 12 reports (five retrospective and seven prospective studies). Most studies of aspirin use reported inverse associations, but only two were statistically significant. The summary OR for the association between aspirin use and prostate cancer was 0.9 (95% confidence interval: 0.82-0.99; test of homogeneity P=0.32), and varied from 1.0 for retrospective studies to 0.85 for prospective studies. Studies that measured exposure to a mixture of NSAIDs were less consistent. These results indicate an inverse association between aspirin use and prostate cancer risk. The current epidemiological evidence and, in particular, the strong and consistent laboratory evidence underline the need for additional epidemiological studies to confirm the direction and magnitude of the association.
Mahmud
S
S
Department of Oncology, McGill University, Gerald Bronfman Centre, 546 Pine Avenue West, Montreal, Quebec, Canada. Salaheddin.mahmud@mcgill.ca
Franco
E
E
Aprikian
A
A
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology* / Q000627:therapeutic use*; D001241:Aspirin / Q000494:pharmacology* / Q000627:therapeutic use*; D016022:Case-Control Studies; D018890:Chemoprevention; D016021:Epidemiologic Studies; D006801:Humans; D008297:Male; D016017:Odds Ratio; D011471:Prostatic Neoplasms / Q000517:prevention & control*; D012189:Retrospective Studies
D000894:Anti-Inflammatory Agents, Non-Steroidal; D001241:Aspirin